The Myeloma Crowd Launches Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform

SALT LAKE CITY, Oct. 2, 2019 /PRNewswire/ — The Myeloma Crowd, a division of the CrowdCare Foundation, today announced the launch of a new study to identify correlations between psoriasis and multiple myeloma. Psoriasis is an auto-immune disease of the skin and multiple myeloma is a rare blood cancer in which the cancer has escaped the immune system.

Participants will join the study via the HealthTree® platform, a new online tool that helps multiple myeloma patients find their best myeloma treatments and accelerate research toward a cure. There are currently more than 4,500 myeloma patients registered to HealthTree.

“This study demonstrates the importance of HealthTree as a tool for patients to connect with opportunities that could help them directly and accelerate a cure,” said Myeloma Crowd founder and myeloma patient Jenny Ahlstrom. “HealthTree has been designed as a model for curing disease by leveraging the crowd, starting with myeloma with the intent of expanding to other cancers and beyond.”

Research shows that multiple myeloma growth and bone damage can occur through activity of the interleukin-17 pathway. IL-17 is also a known treatment target in psoriasis, with several anti-IL-17 monoclonal antibodies currently FDA-approved as psoriasis therapy.  Other joint cytokines and targets may be applicable.

Dana Farber Cancer Institute researchers performed initial work assessing the utility of anti-IL-17 psoriasis mediations to treat multiple myeloma in mouse models. Further research is needed to identify possible connections between the two diseases.

The Myeloma Crowd invites all multiple myeloma patients with psoriasis to join this important study by registering in HealthTree and adding their psoriasis diagnosis to their full health profile.

HealthTree was developed by Myeloma Crowd founders Jenny Ahlstrom, who is also a former Systems Engineer for IBM, and her husband Paul Ahlstrom, an investor and entrepreneur. HealthTree is free for myeloma patients.

To join the psoriasis/myeloma study, create a patient profile on www.healthtree.org. Please note if you have psoriasis in the Full Health Profile and choose to join study by clicking the Accelerate Myeloma Research tile and selecting Yes on the Psoriasis survey question.

About Myeloma Crowd/CrowdCare Foundation

The Myeloma Crowd is a division of the CrowdCare Foundation, a patient-driven 501(c)3 non-profit organization. The Myeloma Crowd provides patient education, advocacy and research funding for multiple myeloma. www.myelomacrowd.org.

 

View original content:http://www.prnewswire.com/news-releases/the-myeloma-crowd-launches-psoriasis–multiple-myeloma-study-using-its-healthtree-platform-300929387.html

SOURCE Myeloma Crowd: CrowdCare Foundation

Staff

Recent Posts

Good Look: A Decade Redefining On-Demand Beauty and Building Toward Unicorn Potential

MIAMI, FL / ACCESS Newswire / January 8, 2026 / What began as a visionary…

3 hours ago

Bionova Scientific and Syenex Forge Strategic Alliance to Expand Access to High-Quality Plasmid DNA for Advanced Therapies

HOUSTON, Jan. 8, 2026 /PRNewswire/ -- Bionova Scientific LLC, an Asahi Kasei company and a…

6 hours ago

Doceree Emerges as Healthcare Marketing’s Most AI-Forward Technology Platform, Building Industry’s First Operating System for the AI Era

Company unifies its AI ecosystem under doceree.ai, launches five industry-first AI solutions, earns top global…

6 hours ago

Longevity “GOAT” Dr. Mark Hyman Joins Jane Fonda as Keynote Speaker for the 2026 Livelong Women’s Health Summit

SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- Livelong Media is proud to announce Dr. Mark…

6 hours ago

Cleanova Strengthens Filtration Portfolio with Strategic Acquisitions of Airflotek and TES-Clean Air Systems, Entering Ultra-Clean Controlled Environment Markets

CHATTANOOGA, Tenn., Jan. 8, 2026 /PRNewswire/ -- Cleanova, a leading global manufacturer of advanced industrial filtration…

6 hours ago

Zifo at JPM Healthcare Conference 2026: Why Technology Alone Cannot Deliver the AI Promise

SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- The life sciences industry is buzzing about AI's…

6 hours ago